- Home
- OMER vs SANA Comparison
OMER vs SANA Comparison
Compare OMER & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- SANA
- Stock Information
- Founded
- OMER 1994
- SANA 2018
- Country
- OMER United States
- SANA United States
- Employees
- OMER N/A
- SANA N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- OMER Health Care
- SANA Health Care
- Exchange
- OMER Nasdaq
- SANA Nasdaq
- Market Cap
- OMER 532.0M
- SANA 522.4M
- IPO Year
- OMER 2009
- SANA 2021
- Fundamental
- Price
- OMER $9.18
- SANA $3.01
- Analyst Decision
- OMER Buy
- SANA Strong Buy
- Analyst Count
- OMER 4
- SANA 4
- Target Price
- OMER $22.50
- SANA $13.00
- AVG Volume (30 Days)
- OMER 422.2K
- SANA 3.3M
- Earning Date
- OMER 03-31-2025
- SANA 02-27-2025
- Dividend Yield
- OMER N/A
- SANA N/A
- EPS Growth
- OMER N/A
- SANA N/A
- EPS
- OMER N/A
- SANA N/A
- Revenue
- OMER N/A
- SANA N/A
- Revenue This Year
- OMER N/A
- SANA N/A
- Revenue Next Year
- OMER N/A
- SANA N/A
- P/E Ratio
- OMER N/A
- SANA N/A
- Revenue Growth
- OMER N/A
- SANA N/A
- 52 Week Low
- OMER $2.61
- SANA $1.52
- 52 Week High
- OMER $13.60
- SANA $12.00
- Technical
- Relative Strength Index (RSI)
- OMER 51.19
- SANA 50.21
- Support Level
- OMER $9.06
- SANA $3.00
- Resistance Level
- OMER $9.43
- SANA $3.35
- Average True Range (ATR)
- OMER 0.52
- SANA 0.24
- MACD
- OMER 0.08
- SANA -0.03
- Stochastic Oscillator
- OMER 52.25
- SANA 50.57
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.